Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nasdaq Biotechnology Ishares ETF (NQ: IBB ) 142.56 +1.05 (+0.74%) Streaming Delayed Price Updated: 3:06 PM EDT, Oct 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Nasdaq Biotechnology Ishares ETF < Previous 1 2 3 4 5 6 7 8 9 ... 24 25 Next > Global Stocks: Breaking Out? January 28, 2023 The S&P 500 is attempting to clear what has been an insurmountable trendline dating back to January 2022. Via Talk Markets The 3 Best Biotech Stocks Under $1 to Buy for January January 26, 2023 Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich. Via InvestorPlace Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug January 06, 2023 Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi. Via Benzinga SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday January 06, 2023 Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to Via Benzinga Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors December 27, 2022 Biopharma stocks were not immune to the broader market downturn seen for much of 2022. Via Benzinga Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro December 19, 2022 The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning. Via Talk Markets Tarsus Added to NASDAQ Biotechnology Index December 16, 2022 From Tarsus Pharmaceuticals, Inc Via GlobeNewswire Small Caps Vs Large Caps: Who Is Leading? December 07, 2022 Clearly, large-cap stocks have been leading with the Dow Jones down the last year to date, but even though the selling pressure has been constant, trading volume has been anemic. Via Talk Markets Meta Platforms, This Biotech ETF And These China Plays Are CNBC's 'Final Trades' December 05, 2022 The iShares Biotechnology ETF (NASDAQ: IBB), which includes several large cap biotechs, has recently narrowed its year-to-date loss to aroun Via Benzinga BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients December 02, 2022 The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. Smart Beta EFTs... Via TheNewswire.com Topics Stocks Exposures Product Safety US Equities BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients December 02, 2022 By Faith Ashmore, Benzinga Via News Direct Exposures Product Safety Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors December 02, 2022 Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. Via Benzinga BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients December 01, 2022 The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. Via Benzinga Will The Dow Jones Continue Higher? Will The Nasdaq Follow? November 29, 2022 It's been a volatile few weeks in the markets, and it can be hard to tell if we're currently in a risk-on or risk-off environment. Via Talk Markets Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead November 28, 2022 Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets. Via Talk Markets Market Currents: Why Pick Stocks? November 28, 2022 Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and... Via Talk Markets Look Who’s Leading Now November 01, 2022 All indexes are near either their 50 or 200 DMA’s as we head into the Fed’s announcement tomorrow. Via Talk Markets Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know November 01, 2022 October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... Via Benzinga Can Biotech Stocks Continue Rallying In This Bear Market? October 31, 2022 Via Talk Markets October Was Not So Scary After All - Things To Keep A Watch Out For October 31, 2022 Via Talk Markets These 4 ETFs Feature on CNBC's 'Final Trades' October 27, 2022 On CNBC’s “Halftime Report Final Trades,” JPMorgan Private Bank’s Anastasia Amoroso chose iShares iBoxx $ High Yield Corporate Bond ETF (NYSE: HYG), saying that she wanted &ldq Via Benzinga Russell 2000: How Money Is Made And Lost In Small Caps October 19, 2022 IWM is in a bearish phase along with the other indices, but recent price action has shown relative strength. Via Talk Markets The Four Indices: Where Each Are In A 4-Year Cycle October 19, 2022 In the aftermath of last week’s market plunge and continued rally since, it is worth noting that the 200-week historic weekly support levels held for the SPY and the DIA, both of which were in danger... Via Talk Markets Steady As She Goes With Healthcare Stocks October 17, 2022 Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports. Via Talk Markets Precarious Action In The Bonds And Stock Market October 16, 2022 Analysts and researchers claimed that double thrusts in the market have always preceded positive returns. Always, huh? Via Talk Markets Taking The Temperature Of The Major Sector ETFs October 12, 2022 One of the most important first steps towards trading success is to tilt your trading towards trending sectors that display strength and avoid market weakness. Via Talk Markets 3 Technical Lessons On Whether Or Not Semiconductors Bottomed October 03, 2022 The semis ETF SMH has three interesting technical features that are a reliable way to assess what to do from here and how to know if this rally will last. Via Talk Markets AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know October 02, 2022 Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... Via Benzinga The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market September 27, 2022 Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market. Via InvestorPlace Step Back To The Monthly Chart On Transportation September 26, 2022 The chart of IYT is a perfect example of the monthly moving average and what to watch for. Via Talk Markets < Previous 1 2 3 4 5 6 7 8 9 ... 24 25 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.